Business Monitor International


Israel Pharmaceuticals & Healthcare Report

Published 01 October 2014

  • 141 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Israel Pharmaceuticals & Healthcare Report

BMI View:   Even though Israel's tense domestic and external situation threatens overall market stability, its pharmaceutical industry remains well positioned for marked over-the-counter and non-patented market growth. Favourable factors include high per capita spending on medicines, a market size approaching USD2bn, a high proportion of pensioners and a largely urbanised population. Moreover, Israel's pharmaceutical market is one of the more advanced in the region, well-developed and export-driven. It is also a very attractive prospect for multinationals looking to launch innovative medicines due to a greater need for specialty treatments, thereby capitalising on the country's strong academic research infrastructure. However, the use of the reference pricing mechanism will lead to further price reductions on medicines. Israel's basket of reference countries are continuing to focus on pharmaceutical prices as a way to contain escalating healthcare costs. We also caution that poor patent respect and a lack of business transparency remain key threats to company revenues.

Headline Expenditure Projections

  • Pharmaceuticals: ILS7.31bn (USD2.02bn) in 2013 to ILS7.53bn (USD2.18bn) in 2014; +3.13% in local currency terms and 7.9% in US dollar terms. Forecast remains broadly in line with Q314, with currency fluctuations driving forecast up in US dollar terms.

  • Healthcare: ILS74.01bn (USD20.50bn) in 2013 to ILS78.62bn (USD22.79bn) in 2014; +6.2% in local currency terms and 11.2% in US dollar terms. Forecast broadly in line with Q314, with currency fluctuations driving forecast up in US dollar terms.

Ri sk/Reward Rating

The Israeli pharmaceutical sector boasts a number of key qualities. These include a largely urbanised population and a significant pensioner proportion. However, we highlight weak intellectual property (IP) laws and long drug approval times as severe hindrances to multinational drugmakers maximising their returns in the market. In BMI's...

Table of Contents

BMI Industry View
7
SWOT Analysis
10
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Israel 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Israel 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Israel 2010-2018)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Israel 2010-2018)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Israel 2010-2018)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Israel 2010-2018)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Israel 2012-2018)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Israel 2012-2018)
30
Other Healthcare Data
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
33
Economic Analysis
33
Table: Economic Activity (Israel 2009-2018)
38
Industry Risk Reward Ratings
39
Middle East & Africa Risk/Reward Ratings
39
Israel Risk/Reward Ratings
46
Reward
46
Risk
47
Market Overview
48
Industry Trends And Developments
49
Epidemiology
49
Communicable Diseases
50
Healthcare Sector
50
Healthcare Insurance
51
Healthcare Coverage Developments
52
Healthcare Financing
53
Healthcare Infrastructure
54
Research And Development Sector
55
Table: Israel's R&D Legislation - Conditions For OCS Funding
56
Clinical Trials
58
Clinical Trial Developments
59
Biotechnology
62
Regulatory Development
65
Regulatory Developments
65
Intellectual Property
66
IP Environment Shortcomings
67
Pricing System
69
Table: Price Build-Up In The Israeli Pharmaceutical Market
70
Reimbursement System
70
Reimbursement Developments
72
Competitive Landscape
73
Pharmaceutical Industry
73
Domestic Pharmaceutical Industry
73
Foreign Pharmaceutical Industry
74
Pharmaceutical Company Developments
74
Pharmaceutical Distribution Sector
81
Pharmaceutical Retail Sector
81
Company Profile
82
Teva Pharmaceutical Industries
82
Taro Pharmaceutical Industries
94
Perrigo (Adis Industries)
98
Dexcel Pharma
102
Neopharm Group
105
Trima
108
Rekah Pharmaceutical Industry
110
Pfizer
112
GlaxoSmithKline
115
Novartis
117
Sanofi
119
Merck & Co
121
Demographic Forecast
123
Table: Israel's Population By Age Group, 1990-2020 ('000)
124
Table: Israel's Population By Age Group, 1990-2020 (% of total)
125
Table: Israel's Key Population Ratios, 1990-2020
126
Table: Israel's Rural/Urban Population Split, 1990-2020
126
Glossary
127
Methodology
129
Pharmaceutical Expenditure Forecast Model
129
Healthcare Expenditure Forecast Model
129
Notes On Methodology
130
Risk/Reward Ratings Methodology
131
Ratings Overview
132
Table: Pharmaceutical Risk/Reward Ratings Indicators
132
Indicator Weightings
133

The Israel Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Israel Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Israeli pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Israel to test other views - a key input for successful budgeting and strategic business planning in the Israeli pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Israeli pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Israel.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc